Vamorolone offers new treatment option with fewer side effects Business Announcement CHILDREN’S NATIONAL HOSPITAL WASHINGTON (October 27, 2023) – Boys with Duchenne muscular dystrophy (DMD) have a clinically proven, new treatment option with the Food and Drug Administration’s approval Thursday of vamorolone, a steroidal-type, anti-inflammatory drug developed based on research performed at Children’s National Hospital. Created...